Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 16 October 2009, 12:08 HKT/SGT
Share:
    

Source: Eisai
Eisai Opens Regional Office in Bahrain

TOKYO, Oct 16, 2009 - (ACN Newswire) - Eisai Co., Ltd. announced today the opening of a regional office in Bahrain. The new office has been established as a branch of its Asian headquarters Eisai Asia Regional Services Pte. Ltd., in Singapore.

Eisai started doing business with the Middle East in the 1960's. It has since focused on the sale of products imported from Japan and up until now has been using local distributors to deliver these in-house developed pharmaceuticals and other products to patients.

This year Eisai launched Methycobal(R), a treatment for peripheral neuropathy, in Saudi Arabia, the biggest market in the Middle East, and the United Arab Emirates, and from next year it also hopes to receive approval to market other new products.

With this in mind, Eisai has been moving forward with preparations for the opening of the Bahrain Regional Office in order to establish an operational base in the area, as it looks towards full-scale business expansion in the Middle East and North Africa in the future. Eisai will commence operations in the region primarily through working with local distributors, while taking responsibility for marketing and registration of pharmaceutical products.

The Middle East and North Africa has a population of over 400 million, and is currently faced with an increase in lifestyle-related diseases such as obesity and diabetes as well as an aging society. Above all, diabetes is one of the issues affecting the region as it has the highest prevalence rate in the world. Eisai expects to make contributions to patients with diabetic neuropathy in the region through the availability of Methycobal.

Eisai currently operates globally in the United States, Europe and Asia. The Company sees the opening of the Bahrain Regional Office as an opportunity to make its in-house products available continuously as well as to actively introduce licensed products, which match the needs of the Middle East and North Africa, thereby contributing to addressing the needs and increasing the benefits of patients and their families in the region.

Outline of Bahrain Regional Office

Registered Company Name:  Eisai Asia Regional Services Pte. Ltd. 
Dated Established:        June 2009 
Location:                 AL-SEEF, Kingdom of Bahrain 
Director:                 Yasushi Okada 
Scope of Business:        Marketing and registration of 
                          pharmaceutical products



Contact:
PR Department
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 14:41 HKT/SGT
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: